Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New disc implant aims to ease chronic back pain without fusion

NCT ID NCT05508360

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This study tests a new disc implant called PerQdisc for people with chronic low back pain from degenerative disc disease. The implant is placed in the spine after removing the damaged disc material. Researchers will track 72 participants to see if the implant improves pain and function, and whether it stays in place safely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PerQdisc Nucleus Replacement System (a disc implant)
What this could lead to
If it works, this could offer a new surgical option for people with chronic low back pain who haven't improved with other treatments.
What could go wrong
This is an early-stage study with only 72 people, so results may not apply to everyone. The implant could fail, move out of place, or require more surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2022

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient is skeletally mature aged 22-70. * Patient has Degenerative Disc Disease (DDD) at one or more levels between L1 and S1 but the discogenic pain must be limited to a single level. * Patient has adequate disc height (6mm) at the level to be treated * Patient has exhausted a minimum of 6 months of conservative treatment for their back (e.g. physical therapy, medications, injections, life style changes, etc). * Patient has a preoperative Oswestry Disability questionnaire score ≥ 40 out of 100 points (40/100) * Patient has a low back pain Visual Analog Scale (VAS) ≥ 40 mm (4 cm) * Patient has signed the approved Informed Consent Form. * All surgeries must be approved by the Medical Advisory Board (MAB) Exclusion Criteria: * Patient has less than 6 mm of disc height. * Patient has had prior lumbar spine surgery (nucleoplasty at non-index level is considered acceptable). * Patient has had spinal fusion in the lumbar or thoracic intervertebral spaces. Cervical fusion is allowed as long as there are no neurologic deficits in the lower extremities. * Patient has spondyloarthropathy or other spondylolisthesis greater than 2 mm. * Patient has congenital moderate or severe spinal stenosis or epidural lipomatosis. * Patient has significant facet disease. Significant is defined as pain improvement of 80% or more following image-guided medial branch blocks of the target level according to SIS guidelines (diagnostic, contrast controlled). * Patient has any known active malignancy. * Patient has previously undergone or currently on immunosuppressive therapy. Steroids used to treat inflammation are allowed. * Patient has active or local systemic infection. * Patient has been diagnosed with hepatitis, rheumatoid arthritis, lupus erythematosus, or other autoimmune disease including AIDS, ARC and HIV. * Patient has diabetes mellitus (Type 1 or 2) requiring daily insulin management. * Patient has osteopenia of the spine (T-score of -1.0 or lower). A DEXA scan should be performed to rule out patients considered at risk for osteopenia. * Patient has morbid obesity defined as a body mass index (BMI) more than 40 or a weight of more than 45 kg (100 lbs.) over ideal body weight. * Patient has a known allergy to silicone or barium sulfate. * Patient has a significant disc herniation at the level to be treated. Significant is defined as a large, extruded herniation that creates a risk for expulsion. * Patient has a significant Schmorl's node in the level to be treated. Significant is defined as a large, rectangular or irregular shaped node that has an associated active inflammatory process (Modic I changes). * Patient has motion of less than 3 degrees on pre-operative lateral flexion/extension radiographs. * Patient belongs to a vulnerable population or has a condition such that his/her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g. developmentally, disabled, prisoner, chronic alcohol/ substance abuser) Intraoperative Exclusion Criteria: * Protrusion of the 20A Imaging Balloon up to or beyond the outer margin of the vertebra during the imaging steps. * Patient has a violated endplate as determined by imaging balloons during fluoroscopy. * Patient has a disc space that is too narrow for implantation. MIPL Specific * Poor radiological visualization of Kambin's triangle. * Sustained irritation of the exiting nerve root during any aspect of the annular dilation technique (leg movement or if performing with electrical monitoring) in spite or repositioning instruments.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic low-back pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    4 sites in 4 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CIGE: Centro de Imunologia y Genetica

    ACTIVE_NOT_RECRUITING

    Medellín, Antioquia, Colombia

  • Cediul S.A.

    ACTIVE_NOT_RECRUITING

    Barranquilla, Atlántico, Colombia

  • Clínica Imbanaco de Cali S.A.

    ACTIVE_NOT_RECRUITING

    Cali, Valle del Cauca Department, Colombia

  • Fundacion Hospitalaria San Vicente de Paul

    ACTIVE_NOT_RECRUITING

    Medellín, Antioquia, Colombia

  • Fundación Campbell

    WITHDRAWN

    Barranquilla, Atlántico, Colombia

  • Life Science Center for Innovation Hospital Clinica Biblica

    RECRUITING

    San José, Costa Rica

  • Pacífica Salud Hospital Punta Pacífica

    RECRUITING

    Panama City, Provincia de Panamá, Panama

    Contact Email: •••••@•••••

  • Republican Specialized Scientific Practical Medical Center of Endocrinology named after Academician Y.Kh. Turakulova

    RECRUITING

    Tashkent, Uzbekistan

  • Sabbag Radiólogos S.A.

    WITHDRAWN

    Barranquilla, Atlántico, Colombia

  • Sanatario Americano

    RECRUITING

    Asunción, 1101, Paraguay

  • Sociedad de Cirugia de Bogota- Hospital de San Jose

    ACTIVE_NOT_RECRUITING

    Bogotá, D.C., Colombia

More trials for these conditions

Other studies related to the condition(s) this trial covers.